Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Alternext  >  Neovacs    ALNEV   FR0004032746

NEOVACS (ALNEV)

 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Alternext
06/19/2017 06/20/2017 06/21/2017 06/22/2017 06/23/2017 Date
0.83(c) 0.82(c) 0.82(c) 0.83(c) 0.82(c) Last
289 995 249 881 122 077 269 606 97 998 Volume
+2.47% -1.20% 0.00% +1.22% -1.20% Change
More quotes
Financials (€)
Sales 2017 7,34 M
EBIT 2017 -9,41 M
Net income 2017 -11,1 M
Debt 2017 -
Yield 2017 -
Sales 2018 7,33 M
EBIT 2018 -9,37 M
Net income 2018 -10,9 M
Debt 2018 -
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales2017 5,85x
Capi. / Sales2018 5,86x
Capitalization 42,9 M
More Financials
Company
Neovacs SA is a biotechnology company which engages in the development of active immunotherapies for treating auto-immune, inflammatory and cancerous diseases.It focuses on the development of Tumor Necrosis Factor-Kinoid for treating Crohn's disease and rheumatoid polyarthritis and... 
More about the company
Latest news on NEOVACS
06/20 NEOVACS : Eovacs announces the completion of patient enrollment in phase...
06/20 NEOVACS : ANNOUNCES THE COMPLETION OF PATIENT ENROLLMENT IN PHASE IIB CLINICAL S..
06/01 NEOVACS : Use of equity line
05/10 NEOVACS : And Lupus Europe Join Voices On World Lupus Day
05/05 NEOVACS : to Present Clinical Development Update On IFNa Kinoid in Dermatomyosit..
05/04 NEOVACS : TO PRESENT CLINICAL DEVELOPMENT UPDATE ON IFNα KINOID...
05/04 NEOVACS : to present clinical development update on IFNalpha Kinoid in dermatomy..
03/30 NEOVACS : provides corporate update and reports full year 2016 financial results
03/23 ORIGINAL-RESEARCH : Neovacs S.A. (von GBC AG): BUY
03/13NEOVACS SA : annual earnings release
More news
Sector news : Biotechnology & Medical Research - NEC
06/23DJOne of the Last Untapped Blockbuster Diseases? Drug Companies Race to Find a ..
06/20 Novartis eye drug works with fewer injections than rival
06/15DJACTELION : J&J Maps Research Plans for Actelion -- WSJ
06/14DJACTELION : Correction to J&J Actelion Story
06/14DJACTELION : J&J Plans to Add Drug Discovery and Early Research to Actelion Unit
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
06/20Neovacs : ANNOUNCES THE COMPLETION OF PATIENT ENROLLMENT IN PHASE IIB CLINICA.. 
05/10Neovacs And Join Voices On World Lupus Day  
03/30Neovacs : provides corporate update and reports full year 2016 financial resu.. 
03/23Original-Research: Neovacs S.A. (von GBC AG): BUY  
03/09Neovacs to Present IFNα Kinoid Technology and Its Clinical Outlooks.. 
More tweets
Qtime:10
Advertisement
Chart NEOVACS
Duration : Period :
Neovacs Technical Analysis Chart | ALNEV | FR0004032746 | 4-Traders
Full-screen chart
Technical analysis trends NEOVACS
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Average target price 2,76 €
Spread / Average Target 237%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Miguel Sieler Chief Executive Officer & Director
Jean-Jacques Bertrand Chairman
Baptiste Pourtout Head-Finance
Géraldine Grouard-Vogel Chief Scientific Officer
Thérèse Croughs Chief Medical Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
NEOVACS1.23%48
INCYTE CORPORATION35.91%27 907
QUINTILES IMS HOLDINGS..19.50%19 657
LONZA GROUP27.74%16 010
CELLTRION, INC.--.--%12 252
ALKERMES PLC5.58%8 957
More Results